An open label clinical trial of reboxetine in patients with major depressive disorder

被引：0
|
作者：
Demir, B
Soykan, A
Devrimci-Ozguven, H
Gögüs, A
Haller, T
机构：
[1] Univ Hacettepe, Dept Psychiat, TR-06100 Ankara, Turkey
[2] Ankara Univ, Dept Psychiat, TR-06100 Ankara, Turkey
[3] Pharmacia Canada, CNS, Markham, ON, Canada
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2002年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S221 / S221
页数：1
相关论文
共 50 条
  • [41] Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder
    Eker, SS
    Akkaya, C
    Akgöz, S
    Sarandöl, A
    Kirli, S
    TURK PSIKIYATRI DERGISI, 2005, 16 (03) : 153 - 163
  • [42] Reboxetine:: a double-blind comparison with fluoxetine in major depressive disorder
    Massana, J
    Möller, HJ
    Burrows, GD
    Montenegro, RM
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (02) : 73 - 80
  • [43] An open trial of nefazodone in HIV+ outpatients with major depressive disorder
    Elliott, AJ
    Russo, J
    RoyByrne, PP
    PSYCHOPHARMACOLOGY BULLETIN, 1997, 33 (03) : 516 - 516
  • [44] Trigeminal nerve stimulation (TNS) for posttraumatic stress disorder and major depressive disorder: An open-label proof-of-concept trial
    Trevizol, Alisson Paulino
    Sato, Isa Albuquerque
    Cook, Ian A.
    Shiozawa, Pedro
    Lowenthal, Rosane
    Cordeiro, Quirino
    EPILEPSY & BEHAVIOR, 2016, 60 : 240 - 241
  • [45] Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: A randomized controlled trial
    Yamada, K
    Yagi, G
    Kanba, S
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2003, 57 (02) : 183 - 187
  • [46] Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder
    Blanco, Carlos
    Hoertel, Nicolas
    Franco, Silvia
    Olfson, Mark
    He, Jian-Ping
    Lopez, Saioa
    Gonzalez-Pinto, Ana
    Limosin, Frederic
    Merikangas, Kathleen R.
    PEDIATRICS, 2017, 140 (06)
  • [47] Mirtazapine augmentation in treatment-resistant major depressive disorder: an open-label, six-week trial
    Aydemir, O
    Taskin, EO
    Deveci, A
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S401 - S402
  • [48] Genito-urinary side effects of reboxetine in males with depressive disorder: Results from an open-label study
    Stamenkovic, M
    El Giamal, N
    Stassny, J
    Gebhart, C
    Scharfetter, J
    Bailer, U
    Tauscher, J
    Kasper, S
    JOURNAL OF AFFECTIVE DISORDERS, 2002, 68 (01) : 135 - 136
  • [49] Feasibility and clinical effects of theta burst stimulation in youth with major depressive disorders: An open-label trial
    Dhami, Prabhjot
    Knyahnytska, Yuliya
    Atluri, Sravya
    Lee, Jonathan
    Courtney, Darren B.
    Croarkin, Paul E.
    Blumberger, Daniel M.
    Daskalakis, Zafiris J.
    Farzan, Faranak
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 258 : 66 - 73
  • [50] Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study
    Hidese, Shinsuke
    Ota, Miho
    Wakabayashi, Chisato
    Noda, Takamasa
    Ozawa, Hayato
    Okubo, Tsutomu
    Kunugi, Hiroshi
    ACTA NEUROPSYCHIATRICA, 2017, 29 (02) : 72 - 79
12345